drugset / Trial / NCT00946348
Cannabis and Schizophrenia: Self-Medication and Agonist Treatment
Phase 1
Completed
12 enrolled
Dartmouth-Hitchcock Medical Center
Columbia University · collabIndiana University · collabNational Institute on Drug Abuse (NIDA) · collabUniversity of Massachusetts, Worcester · collabUniversity of Vermont · collab
RandomizedParallel-groupQuadruple-blindBasic science
Summary
The first aim of this study is to determine whether a brain reward center (BRC) deficiency in patients with schizophrenia (SCZ) and cannabis use disorder (CUD) will be normalized when patients are given cannabis or dronabinol. The second aim will serve to further assess the effects of dronabinol on symptoms and medication side effects in this population.
Timeline
- Start
- 2009-12
- Primary completion
- 2012-10
- Completion
- 2012-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cannabis | Traditional medicine (herbal / TCM) | — | — |
| Subject | Dronabinol | Other / unclassified | 10 mg | Oral |
| Subject | Dronabinol | Other / unclassified | 15 mg | Oral |